Stock Price & Analysis

Based on the provided data and current market conditions, here's my analysis for COR stock:

Technical Analysis

The stock shows a clear upward trend since January 2024, rising from around $210 to current levels near $236. Key technical indicators suggest:

• RSI (14) at 44.19 indicates neutral momentum
• Stock is trading below its 20-day SMA ($248.80) but above 200-day SMA ($234.15)
• Current price is near the lower Bollinger Band, suggesting potential oversold conditions

Fundamental Strength According to recent analysis, Cencora has demonstrated solid business performance:

• Strong Q4 earnings beat with 12.8% YoY revenue growth
• Management raised full-year adjusted EPS guidance by 3% to $15.40
• Consensus EPS growth projection of 11.7% for fiscal 2025

Analyst Sentiment

Wall Street maintains a "Strong Buy" rating:

• 11 Strong Buy recommendations
• 4 Hold ratings
• Mean price target: $282.14 (15.8% upside potential)
• Street-high target: $307 (26% upside)

Recommendation SELL at current levels ($236.22) for these reasons:

1. Stock showing technical weakness below 20-day SMA
2. Recent insider selling activity suggests potential near-term headwinds
3. Current price-to-earnings ratio appears elevated relative to historical averages

Consider re-entering at support levels around $230-232 range, which aligns with the Fibonacci support levels.

Based on the provided data and recent analyst reports, here's a comprehensive price prediction for COR stock in 2025:

Technical Analysis

The stock is currently showing:

• RSI(14) at 44.19 indicating neutral momentum
• MACD divergence with -1.38 suggesting short-term bearish pressure
• Trading below the 20-day SMA of $248.80, indicating near-term weakness

Price Target Analysis Recent analyst price targets for 2025:

• Baird: $307 (Feb 6, 2025)
• BofA: $270 (Feb 5, 2025)
• Leerink: $301 (Feb 5, 2025)

Key Price Drivers

• Strong Q1 FY2025 results with EPS of $3.73 beating estimates by 6%
• Management raised FY2025 EPS guidance to $15.25-$15.55
• Benefiting from industry tailwinds in specialty medications
• Some headwinds in international segment expected to improve in H2 2025

2025 Price Prediction Based on technical indicators, analyst targets, and fundamental factors:

Base Case: $275-285

• Supported by median analyst target around $282
• Assumes continued execution on guidance and market share gains

Bull Case: $300-310

• Aligns with highest analyst targets
• Requires stronger than expected earnings growth and margin expansion

Bear Case: $240-250

• Near current trading levels
• If international headwinds persist or guidance disappoints

Most likely scenario: Base case ($275-285) with 60% probability, given strong fundamentals and analyst consensus but accounting for current technical weakness.

The S1 support level for COR Stock is $239.31 ,The R1 resistant level for COR Stock is $249.27.

As of the end of day on 2025-02-26, the price of COR Stock was $250.53.

The target price for COR Stock according to analyst rating is 281.10, with the highest price target at 308.00 and the lowest at 251.00. Analysts have a Moderate Buy rating on COR Stock overall.

The market cap of COR is $48.5B.

Based on the provided data and recent market developments, here's a comprehensive analysis of COR's valuation:

Technical Analysis

The stock is currently showing signs of consolidation with RSI at 44.19, indicating a neutral momentum. The price is trading between the 20-day SMA ($248.80) and 60-day SMA ($240.82), suggesting a transitional phase.

Valuation Metrics

Current valuation metrics show:

• P/E (FY2023): 21.1x
• EV/EBITDA (FY2023): 11.02x
• P/S (FY2023): 0.14x
• P/B (FY2023): 69.23x
• Dividend Yield: 1.08%

Recent Performance & Market Position According to recent reports, COR has:

• YTD return of 8.4% (outperforming S&P 500's 2.9%)
• Market cap of $47.7 billion
• Strong Q4 earnings with 12.8% YoY revenue growth
• Raised FY25 adjusted EPS guidance to $15.40 (midpoint)

Analyst Consensus

Wall Street maintains a "Strong Buy" rating, with:

• 11 Strong Buy ratings
• 4 Hold ratings
• Mean price target: $282.14 (15.8% upside potential)
• Street-high target: $307 (26% upside)

Conclusion Based on the analysis, COR appears fairly valued to slightly overvalued at current levels. While the company shows strong fundamental growth and positive analyst sentiment, the current technical indicators suggest a neutral stance. The stock's valuation multiples are elevated compared to historical averages, but this is supported by robust earnings growth and raised guidance.

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company is focused on improving the lives of people and animals around the world. It is engaged in the delivery of pharmaceuticals, healthcare products, and solutions. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.

Based on the available data and market analysis, here is the price prediction for COR stock by 2030:

Technical Analysis & Current Position

Growth Projections and Market Position

According to recent analyst reports, Cencora (COR) has shown strong fundamentals with:

• 11.7% projected EPS growth for fiscal 2025
• Consistent earnings beats in the last 4 quarters
• Strong Buy consensus rating from 11 out of 15 analysts
• Current price target of $282.14 (15.8% upside potential)

2030 Price Target: $375-395

The prediction is based on:

1. Strong market position in pharmaceutical distribution and commercialization solutions
2. Consistent earnings growth trajectory and beat history
3. Strategic expansion in wealth solutions platform
4. Current analyst consensus showing bullish outlook with multiple price target raises

The target range assumes:

• Continued 10-12% annual EPS growth
• Stable market multiples
• Successful execution of strategic initiatives
• Maintained leadership in pharmaceutical services

COR has a total of 42000 employees.